Placeholder canvas

Biopharma Deals and Funding Trends – Review of 2022 and Updates through Q1 2023

by Apr 3, 2023Analysis, Funding, M&A, Partnership Deals

Deal Flow in 2022 Returned to pre-2019 Levels

 

Chart showing number of healthcare and life sciences deals by deal type

 

 

Lower Deal Dollars Across All Healthcare and Life Sciences

 

Lower Deal Dollars Across All Healthcare and Life Sciences

 

Licensing Terms are Shifting to More in Milestones

 

Licensing Terms are Shifting to More in Milestones

 

Large Cap Biopharma In-Licensing and Buying in 2022

 

Large Cap Biopharma In-Licensing and Buying in 2022

Big Pharma Pays Well for Phase II as POC Returns

 

Big Pharma Pays Well for Phase II as POC Returns

Large Cap Biopharma Therapy Areas and Modalities in Focus

 

Large Cap Biopharma Therapy Areas and Modalities in Focus

R&D Partnership Activity in Oncology

 

R&D Partnership Activity in Oncology

R&D Partnership Activity in Neurology

 

R&D Partnership Activity in Neurology

R&D Partnership Upfronts in the Top Modalities

 

R&D Partnership Upfronts in the Top Modalities

Healthcare and Life Sciences Venture Returned to pre-2020

 

Healthcare and Life Sciences Venture Returned to pre-2020

All Company Stages Saw Lower Venture Activity

 

All Company Stages Saw Lower Venture Activity

Biopharma M&A Volume Increased in Q1

 

Biopharma M&A Volume Increased in Q1

21,598

Licensing Deals

22,217

Funding Rounds

4,216

M&A

35,278

Company Profiles

5,897

Other Deals

27,588

Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Biopharma Venture Investment Through Q3 2023

Biopharma Venture Investment Through Q3 2023

Biopharma venture investment totals rebounded in Q3 2023, nearing 2020 quarterly levels. The number of rounds, especially for seed and Series A, are still depressed as we are seeing investors re-investing in later rounds of portfolio companies rather than new...

Biopharma M&A Through Q3 2023

Biopharma M&A Through Q3 2023

This is a quick readout of biopharma M&A activity through Q3 2023 as we track the prominent deals for the year leading up to year-end. Among some of the largest in biopharma are Novo Nordisk's acquisition of Inversago Pharma offering shareholders up to $1.075...

Biopharma R&D Partnerships – Q3 2023 Review

Biopharma R&D Partnerships – Q3 2023 Review

Biotech, pharma, and medtech R&D partnerships in Q3 2023 settled to pre-2020 levels on total deal announced values but again on fewer deals. Major deal announcements in Q3 included Pfizer / Flagship Pioneering, Alnylam / Roche, Nanobiotix / Janssen, Orionis /...